Clinical trials
Alzheimer's Disease Dementia clinical trials
Below are recruiting alzheimer's disease dementia clinical trials, each written for real people, not researchers. We’re tracking 471 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07599670RecruitingPhase 1/Phase 2
Safety study of ABBV-1758 injection for Alzheimer's disease
This early-stage trial tests whether ABBV-1758, a new drug given by injection, is safe and effective for people with Alzheimer's disease. The drug targets amyloid, a protein that builds up in the brains of people with Alzheimer's.
Irvine, CaliforniaAges 50–90 - NCT07496021Recruiting
Probiotic for early Alzheimer's: safety and memory benefits
This trial tests a new probiotic (Lactococcus lactis CKDB001) to see if it can slow memory loss in people with early Alzheimer's. It’s a 12-week study that requires a positive amyloid PET scan and allows mild to moderate symptoms.
Gyeonggi-doAges 55–85 - NCT06833645Recruiting
PET scans to spot early Alzheimer's changes
This trial uses special PET scans to see amyloid and tau proteins in the brain, which are linked to Alzheimer's. It aims to find these changes early, in people with mild memory problems or early-stage Alzheimer's.
Chengdu, SichuanAges 18 years+ - NCT07251023RecruitingPhase 3
Testing a new drug for Alzheimer's dementia
This study tests whether a new drug called Latrepirdine (DMB-I) is safe and effective for people with mild to moderate Alzheimer's dementia. It may help slow cognitive decline when added to current treatment or used alone.
Kazan'Ages 60–90 - NCT07214727RecruitingPhase 1
A study of ALN-5288 for Alzheimer's disease
This trial tests an investigational drug called ALN-5288 for people with Alzheimer's disease. It aims to see if the drug is safe and how it affects the body.
MontrealAges 40–80 - NCT07094516RecruitingPhase 2
Testing VHB937 for early Alzheimer's disease
This trial tests a new medicine, VHB937, in people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow down memory loss and thinking problems.
Phoenix, ArizonaAges 50–85 - NCT07011745RecruitingPhase 3
Study of KarXT for Alzheimer's Agitation
This study tests a new drug combination (KarXT + KarX-EC) to see if it can safely reduce agitation in people with Alzheimer's disease. It may help if you or your loved one has bothersome agitation that affects daily life.
Chandler, ArizonaAges 55–90 - NCT06976216RecruitingPhase 3
Study of KarXT plus KarX-EC for Alzheimer's cognitive symptoms
This trial tests a new combination treatment (KarXT plus KarX-EC) to see if it can help with thinking and memory problems caused by Alzheimer's disease. It is for people with mild to moderate Alzheimer's who have a caregiver available.
Long Beach, CaliforniaAges 60–85 - NCT05059158Recruiting
Study how the brain clears amyloid in Alzheimer’s
This trial studies how the brain removes amyloid-β, a protein linked to Alzheimer’s disease. It may help researchers understand what’s happening in people with mild memory impairment or Alzheimer’s, and guide better treatments in the future.
München, BavariaAges 50–85 - NCT06657768RecruitingPhase 1
Study of LY4006895 for healthy people and those with early Alzheimer's
This trial tests a new medicine called LY4006895 in two groups: healthy volunteers and people with early symptomatic Alzheimer's disease. It aims to see how the drug works in the body and if it might help memory and thinking.
Los Alamitos, CaliforniaAges 45–85 - NCT06274528RecruitingPhase 2
DORA and lemborexant in Alzheimer's biomarkers study
This study is testing whether a sleep medication called lemborexant can improve sleep and reduce Alzheimer's-related proteins in healthy older adults with no memory problems. It could help find new ways to delay or prevent Alzheimer's disease.
St Louis, MissouriAges 65 years+ - NCT06189963RecruitingPhase 1/Phase 2
Cell therapy trial for moderate Alzheimer's disease
This trial tests a new immune cell therapy (SNK01) for people with moderate Alzheimer's disease. The goal is to see if it can slow down memory and thinking decline.
Glendale, CaliforniaAges 40–85 - NCT05573490Recruiting
Lifestyle program study for early-onset Alzheimer’s
This study tests a structured lifestyle intervention to help people with early-onset Alzheimer’s disease. It is designed for adults with confirmed Alzheimer’s-related brain changes, and may help with symptoms or day-to-day functioning.
Indianapolis, IndianaAges 40–75 - NCT05020106Recruiting
Tests Alzheimer’s core blood/brain markers to set diagnostic cutoffs
This study checks Alzheimer’s “core biomarkers” to find the best cut-off values for diagnosing Alzheimer’s disease and related conditions. It may help doctors more accurately tell Alzheimer’s, mild cognitive changes, and other causes of memory problems apart.
Beijing, Beijing MunicipalityAges 55–75 - NCT04629547RecruitingPhase 2
Sleep study to help prevent Alzheimer’s disease
This trial tests whether treating sleep issues and measuring sleep can help lower the risk of Alzheimer’s disease before it starts. It focuses on older adults with no dementia signs yet.
St Louis, MissouriAges 65 years+ - NCT03657745Recruiting
40 Hz light and brain training for Alzheimer’s
This trial tests whether a combination of 40 Hz light stimulation and cognitive (thinking) therapy can improve symptoms in people with Alzheimer’s disease. It may help by stimulating the brain and training thinking skills, while carefully checking eye and seizure history.
Miami, FloridaAges 50 years+ - NCT06451952Recruiting
Virtual darkness therapy for agitation in dementia
This trial tests whether virtual darkness therapy (sitting in a dim, calming environment) can reduce agitation in people with dementia. It is designed for patients at NKS Olaviken hospital who have significant agitation.
Askøy, ErdalAges 50 years+ - NCT05643144Recruiting
Shared decisions for dementia and diabetes care
This study tests a program that helps people with both memory problems (like dementia or mild cognitive impairment) and diabetes, along with their caregivers, make better care decisions together. It uses a special device to track blood sugar without fingersticks.
Indianapolis, IndianaAges 65 years+ - NCT06058234Recruiting
Tracking Alzheimer’s treatment for Medicare patients in early stages
This study tracks how well a certain type of Alzheimer’s treatment works for people on Medicare who are in the early stages of the disease. The goal is to collect real-world information about the drug’s benefits and risks.
Baltimore, MarylandAges Any age - NCT06875739Enrolling by invitation
Saliva test for early diagnosis of brain diseases
This study tests whether a saliva sample can help tell the difference between brain diseases like Alzheimer's, Parkinson's, and related conditions. By using a special laser technique, researchers hope to find a quick, non-invasive way to make an earlier and more accurate diagnosis.
CagliariAges 60–85 - NCT07409506Recruiting
How caregivers help people with Alzheimer's
This study looks at the support that caregivers provide to people with Alzheimer's disease at different stages. It helps researchers understand how caregiving changes over time, which can lead to better support for both patients and their families.
VilleurbanneAges 60 years+ - NCT03890861Recruiting
Exercise program to help lower Alzheimer’s risk
This trial studies whether a structured group exercise program can help lower Alzheimer’s disease risk in older African Americans. You would be assigned to a group by chance and asked to attend regular sessions if it’s safe for you to exercise.
Baton Rouge, LouisianaAges 60 years+ - NCT07482800Recruiting
Dementia in stories and real-life medical cases
This study looks at how people with early Alzheimer's or mild memory problems understand stories compared to healthy adults. Your participation could help researchers learn more about how dementia affects thinking and language.
New Taipei CityAges 60–85 - NCT07224607Recruiting
Light therapy for early Alzheimer's disease
This study tests a type of light therapy (called transcranial photobiomodulation) to see if it can help people with early-stage Alzheimer's. It involves coming to Cedars-Sinai for weekly sessions over a period of time.
Los Angeles, CaliforniaAges 55–89
Hear when a new Alzheimer's Disease Dementia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for alzheimer's disease dementia?
- Yes. Clin2 currently lists 471 recruiting alzheimer's disease dementia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a alzheimer's disease dementia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a alzheimer's disease dementia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.